EU regulator issues alert over deaths related to Novartis gene therapy Zolgensma
Novartis in August reported two patient deaths due to acute liver failure after treatment with Zolgensma, which is used to treat spinal muscular atrophy.
(Reporting by Raghav Mahobe in Bengaluru; Editing by…